Gene therapy approaches to HIV infection

American Journal of PharmacoGenomics

Volumn 2, Issue 4, 2002, Pages 245-252

  Lori, Franco ^a,b   Guallini, Paola ^a,b   Galluzzil, Luca ^a,b   Lisziewicz, Julianna ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Research Institute for Genetic Human Therapy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ANTIBODY; COMPLEMENTARY RNA; DNA VACCINE; GAG PROTEIN; LENTIVIRUS VECTOR; POLYETHYLENEIMINE; RECOMBINANT DNA; REV PROTEIN; RIBOZYME; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; VPR PROTEIN; RECOMBINANT PROTEIN; SMALL INTERFERING RNA;

ADENOVIRUS; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; CANARYPOX VIRUS; CELLULAR IMMUNITY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; DOMINANT GENE; DRUG DELIVERY SYSTEM; DRUG DNA BINDING; DRUG EFFECT; DRUG EFFICACY; ENDOCYTOSIS; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE GUN; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HELPER CELL; HERPES VIRUS; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTERMETHOD COMPARISON; LENTIVIRINAE; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT GENE; REVIEW; SALMONELLA; STIMULATION; TRANSGENE; VACCINIA VIRUS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS GENOME; VIRUS REPLICATION; YELLOW FEVER FLAVIVIRUS; ANIMAL; GENETICS; METHODOLOGY;

ADENOVIRIDAE; ALPHAVIRUS; CANARYPOX VIRUS; EQUIDAE; FLAVIVIRUS; HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRUS; SALMONELLA; VACCINIA VIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; YELLOW FEVER VIRUS;

ANIMALS; GENE THERAPY; HIV INFECTIONS; HUMANS; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING;

EID: 0036446806     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200202040-00004     Document Type: Review

References (77)

1. Singwi S, Joshi S. Potential nuclease-based strategies for HIV gene therapy. Front Biosci 2000; 5: D556-79
2. Singwi S, Ramezani A, Ding SF, et al. Targeted RNases: A feasibility study for use in HIV gene therapy. Gene Ther 1999; 6 (5): 913-21
3. Green M, Ishino M, Loewenstein PM. Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 1989; 58 (1): 215-23
4. Hope TJ, McDonald D, Huang XJ, et al. Mutational analysis of the human immunodeficiency virus type 1 Rev transactivator: Essential residues near the amino terminus. J Virol 1990; 64 (11): 5360-6
5. Trono D, Feinberg MB, Baltimore D. HIV-1 gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989; 59: 113-20
6. Yu X, Yuan X, Matsuda Z, et al. The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol 1992; 66 (8): 4966-71
7. Hope TJ, Klein NP, Elder ME, et al. Trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes. J Virol 1992; 66 (4): 1849-55
8. Mautino MR, Keiser N, Morgan RA. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev. J Virol 2001; 75 (8): 3590-9
9. Smythe JA, Sun D, Thomson M, et al. A Rev-inducible mutant gag gene stably transferred into T lymphocytes: An approach to gene therapy against human immunodefficiency virus type 1 infection. Proc Natl Acad Sci U S A 1994 Apr; 91 (9): 3657-61
10. Sawaya BE, Khalili K, Gordon J, et al. Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73. J Virol 2000; 74 (10): 4877-81
11. Todd S, Anderson C, Jolly DJ, et al. HIV protease as a target for retrovirus vector-mediated gene therapy. Biochim Biophys Acta 2000; 1477 (1-2): 168-88
12. Foskett SM, Ghose R, Tang DN, et al. Antiapoptotic function of Cdk9 (TAK/P-TEFb) in U937 promonocytic cells. J Virol 2001; 75 (3): 1220-8
13. Duan L, Bagasra O, Laughlin MA, et al. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci U S A 1994; 91 (11): 5075-9
14. Legastelois I, Desgranges C. Design and intracellular activity of a human singlechain antibody to human immunodeficiency virus type 1 conserved gp41 epitope. J Virol 2000; 74 (12): 5712-5
15. Chen SY, Bagley J, Marasco WA. Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum Gene Ther 1994; 5 (5): 595-601
16. Okui N, Sakuma R, Kobayashi N, et al. Packageable antiviral therapeutics against human immunodeficiency virus type 1: Virion-targeted virus inactivation by incorporation of a single-chain antibody against viral integrase into progeny virions. Hum Gene Ther 2000; 11 (4): 537-46
17. Steinberger P, Andris-Widhopf J, Buhler B, et al. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci U S A 2000; 97 (2): 805-10
18. Morgan RA. Gene therapy for HIV infection. Clin Exp Immunol 1997; 107 Suppl. 1: 41-4
19. Duan L, Zhu M, Ozaki I, et al. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy. Gene Ther 1997; 4 (6): 533-43
20. Lisziewicz J, Sun D, Weichold FF, et al. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci U S A 1994; 91 (17): 7942-6
21. Joshi S, Van Brunschot A, Asad S, et al. Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression. J Virol 1991; 65 (10): 5524-30
22. Weiss B, Davidkova G, Zhou LW. Antisense RNA gene therapy for studying and modulating biological processes. Cell Mol Life Sci 1999; 55 (3): 334-58
23. Veres G, Junker U, Baker J, et al. Comparative analyses ofintracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J Virol 1998; 72 (3): 1894-901
24. Chadwick DR, Lever AM. Antisense RNA sequences targeting the 5' leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle. Gene Ther 2000; 7 (16): 1362-8
25. Donahue RE, Bunnell BA, Zink MC, et al. Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes. Nat Med 1998; 4 (2): 181-6
26. Tanner NK. Ribozymes: The characteristics and properties of catalytic RNAs. FEMS Microbiol Rev 1999; 23 (3): 257-75
27. Dropulic B, Lin NH, Martin MA, et al. Functional characterization of a U5 ribozyme: Intracellular suppression of human immunodeficiency virus type 1 expression. J Virol 1992; 66 (3): 1432-41
28. Weerasinghe M, Liem SE, Asad S, et al. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 1991; 65 (10): 5531-4
29. Koseki S, Tanabe T, Tani K, et al. Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III. J Virol 1999; 73 (3): 1868-77
30. Ramezani A, Joshi S. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo. Antisense Nucleic Acid Drug Dev 1996; 6 (3): 229-35
31. Medina MF, Joshi S. Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes. Nucleic Acids Res 1999; 27 (7): 1698-708
32. Joshi S. Multimeric ribozymes for use in HIV gene therapy. Fourth Cold Spring Harbor Meeting on Gene Therapy; 1998 Sep 23-27; Cold Spring Harbor (NY). New York: Cold Spring Harbor Laboratory, 1998: 245
33. Wang L, Witherington C, King A, et al. Preclinical characterization of an anti-tat ribozyme for therapeutic application. Hum Gene Ther 1998; 9 (9): 1283-91
34. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86 (3): 367-77
35. Paxton WA, Kang S, Koup RA. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression. AIDS Res Hum Retroviruses 1998; 14 Suppl. 1: S89-92
36. Feng Y, Leavitt M, Tritz R, et al. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology 2000; 276 (2): 271-8
37. Cagnon L, Rossi JJ. Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense Nucleic Acid Drug Dev 2000; 10 (4): 251-61
38. Bai J, Rossi J, Akkina R. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy. AIDS Res Hum Retroviruses 2001; 17 (5): 385-99
39. Lisziewicz J, Sun D, Lisziewicz A, et al. Antitat gene therapy: A candidate for late-stage AIDS patients. Gene Ther 1995; 2 (3): 218-22
40. Lee SW, Gallardo HF, Gilboa E, et al. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J Virol 1994; 68 (12): 8254-64
41. Konopka K, Duzgunes N, Rossi J, et al. Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs. J Drug Target 1998; 5 (4): 247-59
42. Lisziewicz J, Zeng G, Gratas C, et al. Combination gene therapy: Synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule. Hum Gene Ther 2000; 11 (6): 807-15
43. Ding SF, Noronha J, Joshi S. Co-packaging of sense and antisense RNAs: A novel strategy for blocking HIV-1 replication. Nucleic Acids Res 1998; 26 (13): 3270-8
44. Rosenberg SA, Blaese RM, Brenner MK, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther 1996; 7 (18): 2287-313
45. Amado RG, Mitsuyasu RT, Zack JA. Gene therapy for the treatment of AIDS: Animal models and human clinical experience. Front Biosci 1999; 4: D468-75
46. Macpherson JL, Ely JA, Sun LQ, et al. Ribozymes in gene therapy of HIV-1. Front Biosci 1999; 4: D497-505
47. Li X, Gervaix A, Kang D, et al. Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: Preclinical studies. Gene Ther 1998; 5 (2): 233-9
48. Morgan RA, Walker R. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Hum Gene Ther 1996; 7 (10): 1281-306
49. Ranga U, Woffendin C, Verma S, et al. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A 1998; 95 (3): 1201-6
50. Wong-Staal F, Poeschla EM, Looney DJ. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther 1998; 9 (16): 2407-25
51. Roe T, Reynolds TC, Yu G, et al. Integration of murine leukemia virus DNA depends on mitosis. EMBO J 1993; 12 (5): 2099-108
52. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 1994; 68 (1): 510-6
53. Zennou V, Petit C, Guetard D, et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101 (2): 173-85
54. Blomer U, Naldini L, Kafri T, et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector, J Virol 1997; 71 (9): 6641-9
55. Naldini L, Blomer U, Gage FH, et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996; 93 (21): 11382-8
56. Kafri T, Blomer U, Peterson DA, et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17 (3): 314-7
57. Miyoshi H, Takahashi M, Gage FH, et al. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A 1997; 94 (19): 10319-23
58. Johnson LG, Olsen JC, Naldini L, et al. Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo. Gene Ther 2000; 7 (7): 568-74
59. Douglas JL, Lin WY, Panis ML, et al. Efficient human immunodeficiency virusbased vector transduction of unstimulated human mobilized peripheral blood CD34+ cells in the SCID-hu Thy/Liv model of human T cell lymphopoiesis. Hum Gene Ther 2001; 12 (4): 401-13
60. Miyoshi H, Smith KA, Mosier DE, et al. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999; 283 (5402): 682-6
61. Curran MA, Kaiser SM, Achacoso PL, et al. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther 2000; 1 (1): 31-8
62. Berkowitz RD, Ilves H, Plavec I, et al. Gene transfer systems derived from Visna virus: Analysis of virus production and infectivity. Virology 2001; 279 (1): 116-29
63. Berkowitz R, Ilves H, Lin WY, et al. Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus. J Virol 2001; 75 (7): 3371-82
64. Olsen JC. Gene transfer vectors derived from equine infectious anemia virus. Gene Ther 1998; 5 (11): 1481-7
65. Lisziewicz J, Galluzzi L, Lori F. Gene therapy for HIV-1. Bundesgesundheitsblatt 2001; 44: 1071-5
66. Mor G. Plasmid DNA: A new era in vaccinology. Biochem Pharmacol 1998; 55 (8): 1151-3
67. Pertmer TM, Eisenbraun MD, McCabe D, et al. Gene gun-based nucleic acid immunization: Elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 1995; 13 (15): 1427-30
68. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993; 90 (24): 11478-82
69. Cohen AD, Boyer JD, Weiner DB. Modulating the immune response to genetic immunization. FASEB J 1998; 12 (15): 1611-26
70. Pertmer TM, Roberts TR, Haynes JR. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 1996; 70 (9): 6119-25
71. Amara RR, Villinger F, Staprans SI, et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002 Aug; 76 (15): 7625-31
72. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical aids in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 492
73. Lisziewicz J, Gabrilovich DI, Varga G, et al. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J Virol 2001; 75 (16): 7621-8
74. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci U S A 1995; 92 (16): 7297-301
75. Labat MF, Steffan AM, Brisson C, et al. An electron microscopy study into the mechanism of gene transfer with lipopolyamines. Gene Ther 1996; 3 (11): 1010-7
76. Pollard H, Remy JS, Loussouam G, et al. Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J Biol Chem 1998; 273 (13): 7507-11
77. Maijgren-Steffensson C, Sonnerborg A, Vahlne A, et al. Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1. Mol Ther 2001; 3 (4): 531-5